Subtype
Malignant Hepatobiliary Neoplasm
CI-CAN-00001136Explore in graph →
1,159 active trials17 approved drugs42 evidence items
- NCIt
- C8609
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00001136Explore in graph →
Clinical trials
5,029 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (563)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT01926236 | Active Symptom Control Alone or With mFOLFOX Chemotherapy for Locally Advanced/ Metastatic Biliary Tract Cancers(ABC06) | completed | Phase 3 | 162 | The Christie NHS Foundation TrustOTHER | 1 | Jan 28, 2020 | clinicaltrials |
| NCT02548780 | LifePearl-Doxo Pharmacokinetic (PK) Study | completed | N/A | 15 | Terumo Europe N.V.INDUSTRY | 3 | Jan 27, 2020 | clinicaltrials |
| NCT03053596 | LifePearl Anthracyclin Registry in Selective Chemo-Embolization of Patients With Unresectable HCC (PARIS Registry) | completed | — | 102 | Terumo Europe N.V.INDUSTRY | 2 | Jan 27, 2020 | clinicaltrials |
| NCT02409524 | An Individualized Anti-Cancer Vaccine in Advanced Hepatocellular Carcinoma Subjects | completed | Phase 2 | 15 | Mirror Biologics, Inc.INDUSTRY | 1 | Jan 22, 2020 | clinicaltrials |
| NCT03159585 | To Evaluate the Efficacy of NY-ESO-1-specific T Cell Receptor Affinity Enhancing Specific T Cell in Solid Tumors | completed | Phase 1 | 6 | Zhujiang HospitalOTHER | 1 | Jan 22, 2020 | clinicaltrials |
| NCT00006251 | Fludarabine Phosphate, Low-Dose Total-Body Irradiation, and Donor Stem Cell Transplant Followed by Cyclosporine, Mycophenolate Mofetil, Donor Lymphocyte Infusion in Treating Patients With Hematopoietic Cancer | completed | Phase 1 / Phase 2 | 21 | Fred Hutchinson Cancer CenterOTHER | 2 | Jan 21, 2020 | clinicaltrials |
| NCT00014235 | Fludarabine Phosphate and Total-Body Radiation Followed by Donor Peripheral Blood Stem Cell Transplant and Immunosuppression in Treating Patients With Hematologic Malignancies | completed | N/A | 160 | Fred Hutchinson Cancer CenterOTHER | 3 | Jan 21, 2020 | clinicaltrials |
| NCT00078858 | Mycophenolate Mofetil and Cyclosporine in Reducing Graft-Versus-Host Disease in Patients With Hematologic Malignancies or Metastatic Kidney Cancer Undergoing Donor Stem Cell Transplant | completed | Phase 1 / Phase 2 | 37 | Fred Hutchinson Cancer CenterOTHER | 3 | Jan 18, 2020 | clinicaltrials |
| NCT02496741 | Metformin And Chloroquine in IDH1/2-mutated Solid Tumors(MACIST) | completed | Phase 1 / Phase 2 | 15 | Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)OTHER | 1 | Jan 9, 2020 | clinicaltrials |
| NCT00003196 | Low-Dose Total Body Irradiation and Donor Peripheral Blood Stem Cell Transplant Followed by Donor Lymphocyte Infusion in Treating Patients With Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia, or Multiple Myeloma | completed | N/A | 63 | Fred Hutchinson Cancer CenterOTHER | 3 | Dec 27, 2019 | clinicaltrials |
| NCT00341705 | The Second Multicenter Hemophilia Cohort Study | completed | — | 2,565 | National Cancer Institute (NCI)NIH | 8 | Dec 17, 2019 | clinicaltrials |
| NCT00825877 | Long-term Follow-up of HALT-C Sustained Virological Responders | completed | — | 140 | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)NIH | 1 | Dec 17, 2019 | clinicaltrials |
| NCT02541370 | Treatment of Relapsed and/or Chemotherapy Refractory Advanced Malignancies by CART133 | completed | Phase 1 / Phase 2 | 20 | Chinese PLA General HospitalOTHER | 1 | Dec 17, 2019 | clinicaltrials |
| NCT02730611 | Metabolic Syndrome, Bile Acids, Hepatocellular Carcinoma and Cholangiocarcinoma(METSLIVER) | completed | — | 124 | Assistance Publique - Hôpitaux de ParisOTHER | 1 | Dec 17, 2019 | clinicaltrials |
| NCT01326702 | Veliparib, Bendamustine Hydrochloride, and Rituximab in Treating Patients With Relapsed or Refractory Lymphoma, Multiple Myeloma, or Solid Tumors | completed | Phase 1 / Phase 2 | 43 | National Cancer Institute (NCI)NIH | 1 | Dec 16, 2019 | clinicaltrials |
| NCT01334112 | Study of Axitinib in Patients With Unresectable Hepatocellular Carcinoma(AXITINIB) | completed | Phase 2 | 30 | University Health Network, TorontoOTHER | 1 | Dec 12, 2019 | clinicaltrials |
| NCT01853618 | Tremelimumab With Chemoembolization or Ablation for Liver Cancer | completed | Phase 1 / Phase 2 | 61 | National Cancer Institute (NCI)NIH | 1 | Dec 10, 2019 | clinicaltrials |
| NCT02774187 | Sorafenib Alone Versus Sorafenib Combined With HAIC for Advanced HCC | completed | Phase 3 | 247 | Sun Yat-sen UniversityOTHER | 1 | Dec 5, 2019 | clinicaltrials |
| NCT01749332 | A Pilot Study of Perihepatic Phlebotomy During Hepatic Resections | completed | N/A | 117 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Dec 3, 2019 | clinicaltrials |
| NCT00908752 | Phase III Trans-Arterial Chemo-Embolization (TACE) Adjuvant HCC(BRISK TA) | completed | Phase 3 | 734 | Bristol-Myers SquibbINDUSTRY | 13 | Dec 2, 2019 | clinicaltrials |
| NCT01185639 | Stereotactic Body Radiation Therapy (SBRT) in Metastatic Non-small Cell Lung Cancer | completed | N/A | 29 | Wake Forest University Health SciencesOTHER | 1 | Nov 29, 2019 | clinicaltrials |
| NCT02643173 | Hepatocellular Carcinoma Recurrence and Anesthesia | completed | — | 259 | Seoul National University Bundang HospitalOTHER | 1 | Nov 22, 2019 | clinicaltrials |
| NCT04172194 | Endoarterial Treatment in Combination With Percutaneous Thermoablation for Medium-sized and Oligonodular Hepatocellular Carcinomas | completed | — | 64 | Centre Hospitalier Universitaire de NiceOTHER | 1 | Nov 21, 2019 | clinicaltrials |
| NCT02592538 | Endobiliary Radiofrequency Ablation With S-1 for Unresectable Cholangiocarcinoma | completed | N/A | 66 | First People's Hospital of HangzhouOTHER | 1 | Nov 19, 2019 | clinicaltrials |
| NCT02652715 | Salvia Hispanica Seed in Reducing Risk of Disease Recurrence in Patients With Non-Hodgkin Lymphoma | completed | N/A | 29 | Mayo ClinicOTHER | 1 | Nov 15, 2019 | clinicaltrials |
| NCT04161911 | A Study to Assess Overall Survival and Treatment Patterns for Advanced Liver Cancer Participants Who Received Nivolumab Therapy | completed | — | 1,426 | Bristol-Myers SquibbINDUSTRY | 1 | Nov 13, 2019 | clinicaltrials |
| NCT01900158 | A Phase I/II Safety and Efficacy Study of PCI of Gemcitabine and Chemotherapy in Patients With Cholangiocarcinomas | completed | Phase 1 | 24 | PCI Biotech ASINDUSTRY | 4 | Oct 29, 2019 | clinicaltrials |
| NCT02259647 | Sorafenib Plus Vitamin K1 Versus Sorafenib in Advanced Hepatocellular Carcinoma | completed | N/A | 60 | Institute of Liver and Biliary Sciences, IndiaOTHER | 1 | Oct 28, 2019 | clinicaltrials |
| NCT03162198 | Frequency of Circulating Tumor Cells (CTCs) and Amount of Cell-free DNA (cfDNA) in Cirrhotic Patients With Hepatocellular Carcinoma (HCC) | completed | — | 53 | Institute of Liver and Biliary Sciences, IndiaOTHER | 1 | Oct 23, 2019 | clinicaltrials |
| NCT03784469 | Effectiveness of Positioning on Back Pain After TACE Among Patients With HCC | completed | N/A | 80 | National Taiwan University HospitalOTHER | 1 | Oct 21, 2019 | clinicaltrials |
| NCT00825955 | Comparison of Brivanib and Best Supportive Care to Placebo for Treatment of Liver Cancer for Those Subjects Who Have Failed Sorafenib Treatment(BRISK PS) | completed | Phase 3 | 587 | Bristol-Myers SquibbINDUSTRY | 19 | Oct 9, 2019 | clinicaltrials |
| NCT00844454 | Multi-pronged Ethanol Ablation and Radiofrequency Ablation of Early-stage Hepatocellular Carcinoma(QPEAvsRFA) | completed | N/A | 81 | Sun Yat-sen UniversityOTHER | 1 | Oct 8, 2019 | clinicaltrials |
| NCT03213314 | HepaT1ca: Quantifying Liver Health in Surgical Candidates for Liver Malignancies(Hepatica) | completed | N/A | 149 | University of EdinburghOTHER | 1 | Oct 4, 2019 | clinicaltrials |
| NCT02773459 | MEK162 in Combination With Capecitabine in Advanced Biliary Tract Cancer | completed | Phase 1 / Phase 2 | 31 | Seoul National University HospitalOTHER | 1 | Sep 30, 2019 | clinicaltrials |
| NCT02387307 | A Study of rSIFN-co in Subjects With Advanced Solid Tumors(rSIFN-01) | completed | Phase 1 | 42 | Sichuan Huiyang Life Science and Technology CorporationINDUSTRY | 1 | Sep 27, 2019 | clinicaltrials |
| NCT02854839 | A Study of MG4101 (Allogeneic Natural Killer Cell) for Intermediate-stage of Hepatocellular Carcinoma | completed | Phase 2 | 78 | GC Cell CorporationINDUSTRY | 1 | Sep 26, 2019 | clinicaltrials |
| NCT01529827 | Fludarabine Phosphate, Melphalan, and Low-Dose Total-Body Irradiation Followed by Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies | completed | Phase 2 | 94 | Roswell Park Cancer InstituteOTHER | 1 | Sep 24, 2019 | clinicaltrials |
| NCT02814461 | The Safety and Maximum Tolerated Dose of Axitinib in Combination With Radiotherapy for HCC | completed | Phase 1 | 9 | Shin Kong Wu Ho-Su Memorial HospitalOTHER | 1 | Sep 23, 2019 | clinicaltrials |
| NCT01850368 | Stereotactic Ablative Radiotherapy for Hepatocellular Carcinoma With Major Portal Vein Invasion | completed | Phase 2 | 35 | Korea Cancer Center HospitalOTHER | 1 | Sep 20, 2019 | clinicaltrials |
| NCT01850667 | Stereotactic Body Radiation Therapy for Hepatocellular Carcinoma | completed | Phase 2 | 74 | Korea Cancer Center HospitalOTHER | 1 | Sep 20, 2019 | clinicaltrials |
| NCT04072250 | Surgery for Recurrent Intrahepatic Cholangiocarcinoma | completed | — | 216 | Chang Gung Memorial HospitalOTHER | 1 | Sep 13, 2019 | clinicaltrials |
| NCT03008343 | Combination of Irreversible Electroporation and NK Immunotherapy for Recurrent Liver Cancer | completed | Phase 1 / Phase 2 | 20 | Fuda Cancer Hospital, GuangzhouOTHER | 1 | Sep 12, 2019 | clinicaltrials |
| NCT02961998 | Preventive Effect of Celecoxib on Sorafenib-related Hand Foot Syndrome, a Single Center, Randomized Controlled Clinical Trail | completed | Phase 4 | 116 | Sun Yat-sen UniversityOTHER | 0 | Sep 10, 2019 | clinicaltrials |
| NCT00858429 | Yttrium Y 90 Glass Microspheres and Capecitabine in Treating Patients With Liver Cholangiocarcinoma or Liver Metastases | completed | Phase 1 | 18 | Northwestern UniversityOTHER | 1 | Sep 9, 2019 | clinicaltrials |
| NCT01287585 | Ph 3 ADI-PEG 20 Versus Placebo in Subjects With Advanced Hepatocellular Carcinoma Who Have Failed Prior Systemic Therapy(ADI-PEG 20) | completed | Phase 3 | 636 | Polaris GroupINDUSTRY | 6 | Sep 6, 2019 | clinicaltrials |
| NCT03516071 | A Phase 2 Study of Brivanib in Chinese Patients With Previously Treated Advanced HCC | completed | Phase 2 | 90 | Zai Lab (Shanghai) Co., Ltd.INDUSTRY | 1 | Sep 4, 2019 | clinicaltrials |
| NCT01837381 | Transarterial Ethanol Ablation(TEA) for Unresectable Hepatocellular Carcinoma(HCC) | completed | N/A | 200 | Chinese University of Hong KongOTHER | 1 | Sep 3, 2019 | clinicaltrials |
| NCT02395250 | Anti-GPC3 CAR T for Treating Patients With Advanced HCC | completed | Phase 1 | 13 | RenJi HospitalOTHER | 1 | Aug 28, 2019 | clinicaltrials |
| NCT02999672 | A Study to Determine Best Tumor Response With Trastuzumab Emtansine in Human Epidermal Growth Factor Receptor 2 (HER2) Overexpressing Solid Tumors(KAMELEON) | completed | Phase 2 | 20 | Hoffmann-La RocheINDUSTRY | 4 | Aug 28, 2019 | clinicaltrials |
Data updated 24 days agoSource updated Jan 28, 2020source: clinicaltrials